CytRx Phase II Trial for ALS (Lou Gehrig's Disease) Expected to Begin After Second Quarter
Monday June 20, 8:30 am ET
Company responds to FDA request for information regarding arimoclomol
CytRx Corporation (Nasdaq: CYTR - News), a biopharmaceutical company engaged in the development and...
ability
als
brain
candida
clinical
clinical trial
diagnosis
documents
familial
fda
food
information
lou gehrig's disease
medical
movement
muscles
neurology
professor
research
robert
sod1
testing
treatment
trial
worldwide